Temporary and voluntary hold on manufacturing and release of anaesthetic medicines Ultiva®, Tracrium® & Mivacron® at its manufacturing site

GSK would like to inform healthcare professionals of a temporarily and voluntary hold on manufacturing and release of the anaesthetic medicines ULTIVA^® For Injection 1mg/vial (Remifentanil Hydrochloride), TRACRIUM^® Injection 10mg/ml (5ml ampoule) (Atracurium Besylate), MIVACRON^® Injection 2mg/ml (10ml ampoule) (Mivacurium chloride), from its Parma manufacturing site. This was a precautionary measure while GSK investigated and resolved an issue with data inconsistencies at this facility. There are no concerns over the quality of products already distributed or those held locally at warehouses. GlaxoSmithKline (GSK) is advising healthcare providers of a potential and temporary lack of disruption to the availability of the above listed anaesthetic products. In view of the anticipated tight supply of these medicines, healthcare providers are recommended to consider alternatives in place of the above medicines during this period of time. Please refer to the Dear Healthcare Professional Letter (DHCPL) for more details.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.